Replimune: Modeling The Coin Flip Of FDA Approval
Replimune Group, Inc. is facing a critical FDA decision regarding its drug RP1 for advanced melanoma. The current market valuation suggests a 50% chance of approval, which could significantly increase the stock price. However, the risks associated with potential outcomes lead to a cautious 'Hold' rating from analysts.
- ▪Replimune is awaiting a third FDA decision on its drug RP1 for advanced melanoma.
- ▪The stock could rise to $14.99 per share if RP1 is approved.
- ▪Conversely, a third Complete Response Letter may reduce the stock value to around $3.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4912217-replimune-stock-modeling-fda-approval-maintain-hold"},"author":{"@type":"Person","name":"Stephen Ayers","url":"https://seekingalpha.com/author/stephen-ayers"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
